EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Danielle Brazel, Misako Nagasaka iD

Targeted Oncology · 2024-05 · 19 (3) · 297-301

DOI: 10.1007/s11523-024-01055-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Targeted Oncology, online erschienen am 13.05.2024. Verfasst von Danielle Brazel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, 10166 N Torrey Pines Rd, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kristen Rat Sarcoma viral oncogene (KRAS) mutations are one of the most common oncogenic drivers found in 12-14% of non-small cell lung cancer (NSCLC) and 4% of colorectal cancer tumors. Although previously difficult to target, sotorasib and adagrasib are now approved for previously treated NSCLC patients with KRAS G12C mutations. In preclinical studies, divarasib was 5 to 20 times as potent and up to 50 times as selective as sotorasib and adagrasib. While sotorasib met its primary endpoint in the phase III second line study against docetaxel, the progression-free survival (PFS) benefit was small and no overall survival (OS) benefit was observed. Adagrasib has demonstrated clinical benefit in the phase I/II KRYSTAL-1 study setting, however, 44.8% of patients reported grade 3 or higher toxicities. Divarasib has been studied in a phase I dose expansion cohort with promising efficacy [objective response (ORR) 53.4% and PFS 13.1 months]. Although most patients reported toxicities, the majority were low-grade and manageable with supportive care. Here we discuss these results in the context of the evolving KRAS G12C landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins p21(ras)Humans

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, 10166 N Torrey Pines Rd, La Jolla, CA, USA.
  • Chao Family Cancer Center, UCI Medical Center, University of California Irvine School of Medicine, 101 The City Drive, Orange, CA, 92868, USA. nagasakm@hs.uci.edu.
  • St. Marianna University School of Medicine, Kawasaki, Japan. nagasakm@hs.uci.edu.

ORCID-Profile: Misako Nagasaka

Zitieren

APA

Brazel, D., & Nagasaka, M. (2024). Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Targeted Oncology, 19(3), 297-301. https://doi.org/10.1007/s11523-024-01055-y

Vancouver

Brazel D, Nagasaka M. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Targeted Oncology. 2024;19(3):297-301. doi:10.1007/s11523-024-01055-y

BibTeX
@article{Brazel2024,
  author = {Brazel, Danielle and Nagasaka, Misako},
  title = {Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC},
  journal = {Targeted Oncology},
  year = {2024},
  volume = {19},
  number = {3},
  pages = {297--301},
  doi = {10.1007/s11523-024-01055-y}
}
Kostenlos starten →